Related Experiment Videos
ATP-site directed inhibitors of cyclin-dependent kinases
1University of California, Department of Chemistry, 824 Latimer Hall, Berkeley, California, USA.
Abstract:
Cyclin-dependent kinases trigger and coordinate transitions between different phases the cell division cycle (CDK1, 2, 3, 4, 6, 7). They also play a role in apoptosis (CDK2), in neuronal cells (CDK5) and in the control of transcription (CDK 7, 8, 9). Intensive screening has lead to the recent identification of a series of chemical inhibitors of CDKs: olomoucine, roscovitine, purvalanol, CVT-313, flavopiridol, g-butyrolactone, indirubins, paullones and staurosporine. Some of these compounds display remarkable selectivities and efficiencies (IC50 < 25 nM). Many have been co-crystallised with CDK2 and their interactions with the kinase have been analysed in atomic detail. These inhibitors all act by competing with ATP for binding at the catalytic site. Most inhibitors present a flat heterocyclic ring system that occupies the purine binding pocket as well as form 2 or 3 hydrogen bonds with Glu-81 and Leu-83. The binding modes of these inhibitors are reviewed in this article. Knowledge of the CDK/inhibitor interactions will be of great help to design inhibitors with improved selectivity our potency as well as to generate affinity chromatography matrices for the purification and identification of their cellular targets. The potential use of CDK inhibitors is being extensively evaluated in cancer chemotherapy and other fields such as the cardiovascular domain (restenosis), dermatology (psoriasis), nephrology (glomerulonephritis) parasitology (unicellular parasites such as Plasmodium, Trypanosomes, Toxoplasm,.etc.), neurology (Alzheimer's disease) and viral infections (cytomegalovirus, H.I.V., herpes).
Insights
Cyclin-dependent kinases (CDKs) regulate cell division and transcription. Chemical inhibitors targeting CDKs show high efficacy and selectivity, offering potential for cancer chemotherapy and other diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Cyclin-dependent kinases (CDKs) are crucial regulators of the cell cycle, apoptosis, neuronal function, and transcription.
- Dysregulation of CDK activity is implicated in various diseases, including cancer.
Purpose of the Study:
- To review the binding modes of recently identified chemical inhibitors of CDKs.
- To highlight the potential of these inhibitors in therapeutic applications.
Main Methods:
- Intensive screening for CDK inhibitors.
- Co-crystallization of inhibitors with CDK2.
- Analysis of atomic-level interactions between inhibitors and CDK2.
Main Results:
- A series of potent and selective chemical CDK inhibitors have been identified (e.g., olomoucine, roscovitine, flavopiridol).
- These inhibitors compete with ATP at the catalytic site, forming hydrogen bonds with key residues (Glu-81, Leu-83).
- Structural analysis reveals detailed binding interactions.
Conclusions:
- Understanding CDK/inhibitor interactions facilitates the design of more potent and selective inhibitors.
- CDK inhibitors hold significant therapeutic potential for cancer and other diseases like Alzheimer's and viral infections.